The American Journal of Managed Care

MajesTEC-3 and the Future of Combination Regimens in Multiple Myeloma

Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...
Healio

Combination induces durable responses in advanced multiple myeloma

Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...
Morningstar

Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma

LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with ...
Nasdaq

Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated initially in combinations that could address over half of patients with colorectal cancer SAN DIEGO, Sept. 22, 2021 (GLOBE ...